Leveraging WES data to identify biomarker signatures

Precision Biomarker Discovery in Cancer Immunotherapy

Our client’s requirement

Our Pharma client from the US operating in the Immuno-oncology field partnered with Excelra to help decipher precise biomarker signatures linked to the effectiveness and resistance of immunotherapy in Small Cell Carcinoma and Renal Cell Carcinoma. To achieve this, the approach involved an intricate analysis encompassing gene expression profiles, somatic mutations, and insights into the tumor microenvironment. Additionally, they required validated and optimized code to streamline and enhance the accuracy of their research process.

Our approach

Drawing from extensive Whole Exome Sequencing (WES) data, we crafted precise co-expression networks using cutting-edge algorithms, revealing robust gene modules intricately linked to varied clinical traits. Integrating mutation profiles with advanced computational models unraveled the intricate mechanisms steering immunotherapy efficacy and resistance. This method provided nuanced insights into genetic mutations, gene expression, and clinical outcomes. Additionally, our approach involved identifying biomarker signatures within clinical data and aligning them with the client’s Intellectual Property (IP), alongside code validation and optimization.